Skip to main
  1. Stocks
  2. Tarsus Pharmaceuticals
  3. Forecast
TARS

Tarsus Pharmaceuticals (TARS) Stock Forecast & Price Target

Tarsus Pharmaceuticals (TARS) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tarsus Pharmaceuticals is attractive because XDEMVY is delivering exceptional commercial momentum, with 3Q26 sales of $194.6MM, up 64% year over year, and cumulative net sales now above $1B on more than one million bottles dispensed since launch. Management’s raised FY26 guidance to $715-730MM, alongside record prescriptions, about 20% growth in daily prescribers, and retreatment near 20%, suggests expanding physician adoption and durable demand rather than a one-time launch spike. The outlook is further supported by a cash balance of $309.6MM, a broadening pipeline with TP-04 and TP-05 Phase II topline data on track for 1H27, and added upside from gildeuretinol and IRX-101 acquisitions.

Bears say

Tarsus Pharmaceuticals is vulnerable to a concentrated product-risk profile, as XDEMVY is the main commercial driver and any emergence of a safety issue could quickly undermine adoption, physician confidence, and revenue durability. Its growth thesis also faces launch slowdown as penetration nears peak, while pricing pressure from IRA negotiation or most-favored-nation policy could compress margins and limit the profitability of its ophthalmology franchise. Beyond the core launch, competition in Demodex blepharitis and Stargardt disease, limited exclusivity for gildeuretinol, and potential delays in pipeline programs such as NORTHSTAR and COMFORT increase execution risk and weaken the case for sustained fundamental upside.

Tarsus Pharmaceuticals (TARS) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tarsus Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Tarsus Pharmaceuticals (TARS) Analyst Forecast & Price Prediction

Get the latest Tarsus Pharmaceuticals (TARS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Tarsus Pharmaceuticals (TARS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tarsus Pharmaceuticals (TARS) Forecast

Analysts have given Tarsus Pharmaceuticals (TARS) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Tarsus Pharmaceuticals (TARS) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $104.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $104.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tarsus Pharmaceuticals (TARS)


Tarsus Pharmaceuticals (TARS) Analyst Forecast & Price Prediction

Get the latest Tarsus Pharmaceuticals (TARS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Tarsus Pharmaceuticals (TARS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TARS stock data and trends